Would you offer chemotherapy to a postmenopausal woman with microinvasive ER/PR positive, Her2 negative invasive ductal carcinoma with a single lymph node metastasis and insufficient tissue for Oncotype testing?   

I would want to obtain information about how strongly ER and/or PR positive the cancer was on IHC, and also the size of the lymph node metastasis. The other information that would play a role for me here would be the patient's age, Ki67 (if available), tumor grade, and any other comorbidities. Since...

Agree with the above. Other ways to predict the benefit/impact of chemotherapy include tools such as Predict UK and also Magee equations to help gather information to counsel the patient.